ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Anti-TMEFF2/Anti-CD3 Bispecific Antibody JNJ-70218902

Its studies are mostly in Leukemia, Myeloid, Acute · Neoplasms, led by Johnson & Johnson.

Furthest: phase 1, since May 18, 20202 company-led studies, 1 open or runningNext primary completion: Jan 19, 2028 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Johnson & Johnson21 open or runningphase 1since May 18, 2020May 18, 2020Jan 19, 2028phase 1 · NCT06788509

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 18, 2020First study: phase 1 study in NeoplasmsFirst studyNCT04397276 · 82 enrolled · Canada, Israel, Spain
  2. Jan 16, 2025Phase 1 study in Leukemia, Myeloid, AcuteNCT06788509 · 120 planned · Australia, Belgium, Denmark and more

Ahead

  1. Jan 19, 2028Primary completion: phase 1 study in Leukemia, Myeloid, AcuteNCT06788509

TargetBeta

CD3E →TMEFF2 →read by rule
“A T-cell redirecting agent and bispecific antibody targeting both the prostate cancer lineage antigen tomoregulin-2 (transmembrane protein with EGF-like and two follistatin-like domains 2; TMEFF2; TENB2) and the T-cell surface receptor CD3, ”NCIt, by rule

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06788509Leukemia, Myeloid, Acute · Australia, Belgium, Denmark and more1By invitationJan 19, 2028120
NCT04397276Neoplasms · Canada, Israel, Spain1CompletedSep 16, 202582

How it is read

Names in the registry

  • “JNJ-70218902”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.